Literature DB >> 6624137

Influence of 9-hydroxyellipticine and 3-methylcholanthrene treatment on antipyrine metabolite formation in rats in vivo.

M W Teunissen, R P Joeres, N P Vermeulen, D D Breimer.   

Abstract

The influence of pretreatment of rats with 9-hydroxyellipticine and 3-methylcholanthrene on different enzymes of the hepatic mixed-function oxidase system were studied using antipyrine as model compound. Antipyrine half-lives and clearances were estimated in blood, and the metabolite profile was determined in urine. 3-Methylcholanthrene treatment resulted in an increase in antipyrine clearance from 17 to 75 ml/min per kg. Partial clearance of formation of 4-hydroxyantipyrine was selectively increased from 3.9 to 28.2 ml/min kg, whereas clearance of 3-hydroxymethylantipyrine was decreased from 3.2 to 1.2 ml/min per kg. Norantipyrine formation was increased from 2.7 to 7.2 ml/min per kg, while 4,4'-dihydroxyantipyrine formation was unchanged. 9-Hydroxyellipticine treatment resulted in no change in the total clearance, and only the clearance of 4,4'-dihydroxyantipyrine was decreased, from 2.5 to 1.5 ml/min per kg. After pretreatment with 3-methylcholanthrene, 9-hydroxyellipticine treatment resulted in a selective decrease in the clearances of 4-hydroxyantipyrine, from 28.2 to 15.8 ml/min per kg, and of 4,4'-hydroxyantipyrine, from 3.8 to 1.6 ml/min per kg. From these results it is concluded, that 9-hydroxyellipticine is a selective inhibitor of the activity of some of the cytochrome P-450s involved in antipyrine metabolism, though this inhibition does not effect all of these enzymes, nor is it restricted to polycyclic hydrocarbon-induced activity. These results further substantiate the value of antipyrine as a model substrate, for they indicate that the formation of all four metabolites of antipyrine in rats is mediated by different (iso-)enzymes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6624137     DOI: 10.3109/00498258309052258

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  10 in total

1.  Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.

Authors:  E Perucca; R Grimaldi; G M Frigo; A Sardi; H Mönig; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.

Authors:  J H Jonkman; K G Nicholson; P R Farrow; M Eckert; G Grasmeijer; B Oosterhuis; O E De Noord; T W Guentert
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

3.  Effect of deltamethrin on antipyrine pharmacokinetics and metabolism in rat.

Authors:  A Anadón; M R Martinez-Larrañaga; M J Díaz; P Bringas; M C Fernandez
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

4.  Antipyrine metabolite formation and excretion in patients with chronic renal failure.

Authors:  M W Teunissen; D Kampf; I Roots; N P Vermeulen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Influence of cimetidine on steady state concentration and metabolite formation from antipyrine infused with a rectal osmotic mini pump.

Authors:  M W Teunissen; C H Kleinbloesem; L G de Leede; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.

Authors:  M W Teunissen; P Spoelstra; C W Koch; B Weeda; W van Duyn; A R Janssens; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

7.  Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.

Authors:  P N Shaw; J B Houston; M Rowland; K Hopkins; J F Thiercelin; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

8.  Influence of alaproclate on antipyrine metabolite formation in man.

Authors:  M W Teunissen; A Wahlén; E Vinnars; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Antipyrine metabolism in patients with disseminated testicular cancer and the influence of cytostatic treatment.

Authors:  M W Teunissen; P H Willemse; D T Sleijfer; W J Sluiter; D D Breimer
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

10.  Correlation between in vivo antipyrine metabolite formation and theophylline metabolism in rats.

Authors:  M W Teunissen; I O Brorens; H J De Langen; A M Geerlings; D D Breimer
Journal:  Pharm Res       Date:  1986-06       Impact factor: 4.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.